OPKO Health will report Q4 and FY 2025 results on February 26, 2026, with a conference call at 4:30 PM ET.
Quiver AI Summary
OPKO Health, Inc. will announce its operating and financial results for the three and twelve months ending December 31, 2025, on February 26, 2026, after U.S. market close. Following the release, senior management will provide a business update and discuss the results during a conference call and live audio webcast starting at 4:30 p.m. Eastern Time. Interested participants are encouraged to pre-register to access the call more easily, although others can join via standard dialing. A telephone replay will be available until March 5, 2026, and a webcast replay will be accessible shortly after the live event. OPKO is a biopharmaceutical and diagnostics company focused on establishing leading positions in growing markets through its innovative technologies.
Potential Positives
- OPKO Health is scheduled to report its operating and financial results for the fourth quarter and full year 2025, providing stakeholders with important updates on the company's performance.
- The conference call and webcast will include a business update and financial guidance from senior management, indicating transparency and engagement with investors.
- Participants have the option to pre-register for the conference call, enhancing accessibility and streamlining the communication process for stakeholders.
Potential Negatives
- None
FAQ
What date will OPKO Health report their financial results?
OPKO Health plans to report its financial results on February 26, 2026.
What time is the OPKO Health conference call scheduled?
The conference call is scheduled to begin at 4:30 p.m. Eastern time.
How can I join the OPKO Health conference call?
Participants can pre-register for the call or dial in using provided numbers.
Where can I find the webcast of the OPKO Health call?
The webcast can be accessed on OPKO’s Investor Relations page.
How long will the telephone replay of the conference be available?
The telephone replay will be available until March 5, 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPK Insider Trading Activity
$OPK insiders have traded $OPK stock on the open market 33 times in the past 6 months. Of those trades, 33 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $OPK stock by insiders over the last 6 months:
- PHILLIP MD ET AL FROST (CEO & Chairman) has made 33 purchases buying 2,423,300 shares for an estimated $3,191,591 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$OPK Hedge Fund Activity
We have seen 86 institutional investors add shares of $OPK stock to their portfolio, and 94 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 5,078,109 shares (-13.5%) from their portfolio in Q4 2025, for an estimated $6,398,417
- WEISS ASSET MANAGEMENT LP removed 3,626,221 shares (-76.2%) from their portfolio in Q3 2025, for an estimated $5,620,642
- GOLDMAN SACHS GROUP INC added 3,600,378 shares (+150.9%) to their portfolio in Q4 2025, for an estimated $4,536,476
- MARSHALL WACE, LLP removed 3,348,166 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,189,657
- WHITEFORT CAPITAL MANAGEMENT, LP added 3,125,800 shares (+176.2%) to their portfolio in Q3 2025, for an estimated $4,844,990
- AQR CAPITAL MANAGEMENT LLC added 1,937,516 shares (+207.0%) to their portfolio in Q3 2025, for an estimated $3,003,149
- GRAHAM CAPITAL MANAGEMENT, L.P. removed 1,812,763 shares (-94.9%) from their portfolio in Q3 2025, for an estimated $2,809,782
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OPK Price Targets
Multiple analysts have issued price targets for $OPK recently. We have seen 2 analysts offer price targets for $OPK in the last 6 months, with a median target of $1.925.
Here are some recent targets:
- Maury Raycroft from Jefferies set a target price of $1.6 on 10/31/2025
- Michael Petusky from Barrington Research set a target price of $2.25 on 10/30/2025
Full Release
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link . Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here .
A telephone replay will be available until March 5, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 2367034. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here .
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com .
Contacts:
Alliance Advisors IR
Yvonne Briggs, 310-691-7100
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]
